Alveda Pharmaceuticals Inc.

alvedapharma.com

Responsible for the overall day-to-day operations. Responsible for the smooth operation of the process of producing and distributing the company's goods or of providing its services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

WORKFORCE DRUG TESTING POSITIVITY CLIMBED TO HIGHEST RATE IN 16 YEARS, NEW QUEST DIAGNOSTICS DRUG TESTING INDEX™ ANALYSIS FINDS

Prnewswire | August 25, 2020

news image

The rate of workforce drug positivity hit a sixteen-year high in 2019, according to a new analysis released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Positivity rates in the combined U.S. workforce increased in urine drug tests, climbing to the highest level since 2003 (4.5%) and more than 28% percent higher than the thirty-year low of 3.5 percent recorded between 2010 and 2012. In addition to overall increases in workforce drug ...

Read More

BUSINESS INSIGHTS

ZENAS BIOPHARMA ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO OBEXELIMAB FROM XENCOR

Xencor, Zenas BioPharma | November 22, 2021

news image

Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (“Zenas”), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelima...

Read More

BUSINESS INSIGHTS

GNS HEALTHCARE AND ARVINAS ENTER INTO NEUROSCIENCE DRUG DISCOVERY COLLABORATION

GNS Healthcare | May 10, 2022

news image

GNS Healthcare, the leader in the use of "Virtual Patients", Causal AI and simulation technology for biopharmaceutical companies, today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to generate insights to help accelerate drug development for neurodegenerative diseases. Every year more than six million patients in the United States alone are diagnose...

Read More

PHARMACY MARKET

AIKIDO PHARMA REPORTS IMPROVED MANUFACTURING PROCESS AND NEW UNITED STATES PATENT FOR PANCREATIC DRUG

AIkido Pharma Inc. | March 04, 2022

news image

AIkido Pharma Inc.reported an improvement in the manufacturing process for its pancreatic cancer drug, DHA-dFdC, licensed from the University of Texas at Austin. The Company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug. With respect to manufacturing process, the Company reported the successful development of a new means for the scaled pro...

Read More
news image

WORKFORCE DRUG TESTING POSITIVITY CLIMBED TO HIGHEST RATE IN 16 YEARS, NEW QUEST DIAGNOSTICS DRUG TESTING INDEX™ ANALYSIS FINDS

Prnewswire | August 25, 2020

The rate of workforce drug positivity hit a sixteen-year high in 2019, according to a new analysis released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Positivity rates in the combined U.S. workforce increased in urine drug tests, climbing to the highest level since 2003 (4.5%) and more than 28% percent higher than the thirty-year low of 3.5 percent recorded between 2010 and 2012. In addition to overall increases in workforce drug ...

Read More
news image

BUSINESS INSIGHTS

ZENAS BIOPHARMA ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO OBEXELIMAB FROM XENCOR

Xencor, Zenas BioPharma | November 22, 2021

Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (“Zenas”), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelima...

Read More
news image

BUSINESS INSIGHTS

GNS HEALTHCARE AND ARVINAS ENTER INTO NEUROSCIENCE DRUG DISCOVERY COLLABORATION

GNS Healthcare | May 10, 2022

GNS Healthcare, the leader in the use of "Virtual Patients", Causal AI and simulation technology for biopharmaceutical companies, today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to generate insights to help accelerate drug development for neurodegenerative diseases. Every year more than six million patients in the United States alone are diagnose...

Read More
news image

PHARMACY MARKET

AIKIDO PHARMA REPORTS IMPROVED MANUFACTURING PROCESS AND NEW UNITED STATES PATENT FOR PANCREATIC DRUG

AIkido Pharma Inc. | March 04, 2022

AIkido Pharma Inc.reported an improvement in the manufacturing process for its pancreatic cancer drug, DHA-dFdC, licensed from the University of Texas at Austin. The Company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug. With respect to manufacturing process, the Company reported the successful development of a new means for the scaled pro...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us